PsychoGenics, in collaboration with the Charcot-Marie-Tooth Association (CMTA), is at the forefront of this research, devoted to the exploration and development of potential therapies for CMT.
Charcot-Marie-Tooth disease is a hereditary neurological disorder characterized by peripheral nerve damage, resulting in muscle weakness and sensory loss. Its genetic complexity and varied manifestations underscore the necessity for precise preclinical studies.
Collaboration with CMTA: Enhancing Preclinical CMT Research
Our partnership with the Charcot-Marie-Tooth Association (CMTA) amplifies our research capabilities to accelerate therapeutic development for CMT. Together, we execute studies and leverage our mutual expertise to evaluate potential therapies in rodent models of CMT1A, 2A, and 2E. Longitudinal motor function, nerve conduction, and compound muscle action potential studies can be performed in these models and the full suite of our biomarker analysis capabilities can be applied as needed. Contact us or directly connect with the CMTA to learn more about available resources for preclinical testing in CMT rodent models.
Driving Breakthroughs in Preclinical CMT Research
Through our collaborative efforts, PsychoGenics aims to drive your breakthrough to discover more effective treatments for CMT. By combining our knowledge, resources, and commitment, we strive to make a meaningful impact in the lives of individuals affected by this challenging condition.
Explore our areas of neuromuscular disorder specialization: